Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells

M. Onimaru, K. Ohuchida, T. Egami, K. Mizumoto, E. Nagai, L. Cui, H. Toma, K. Matsumoto, M. Hashizume, M. Tanaka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Adenovirus-mediated gene therapy shows remarkable promise as a new strategy for advanced pancreatic cancer, but satisfactory clinical results have not yet been obtained. To improve this gene therapy, we investigated the effects of gemcitabine (GEM) on transgene expression by adenoviral vectors and their biological effects. We used Ad-lacZ and adenoviral vector-expressing NK4 (Ad-NK4) as representative adenoviral vectors. These vectors express Β-galactosidase (Β-gal) and NK4 (which inhibits the invasion of cancer cells), respectively, under the control of the CMV promoter. Cells were infected with the individual adenoviruses and then treated with GEM. GEM increased Β-gal mRNA expression and Β-gal activity, and increased NK4 expression in both culture media and within infected cells, in dose-dependent manners. The increased expression of NK4 delivered by Ad-NK4 had biological effects by inhibiting the invasion of cancer cells. GEM also enhanced NK4 expression in SUIT-2 cells transfected with an NK4-expressing plasmid, suggesting that GEM enhanced CMV promoter activity. In in vivo experiments, NK4 expression within subcutaneously implanted tumors was increased in GEM-treated mice compared with control mice. These results suggest that adenovirus-mediated gene therapy with GEM may be a promising approach for treating pancreatic cancer, and that this combination therapy may decrease the risks of side effects.

Original languageEnglish
Pages (from-to)541-549
Number of pages9
JournalCancer Gene Therapy
Volume17
Issue number8
DOIs
Publication statusPublished - Aug 1 2010

Fingerprint

gemcitabine
Pancreatic Neoplasms
Adenoviridae
Genetic Therapy
Galactosidases
Neoplasms
Transgenes
Culture Media
Plasmids

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells. / Onimaru, M.; Ohuchida, K.; Egami, T.; Mizumoto, K.; Nagai, E.; Cui, L.; Toma, H.; Matsumoto, K.; Hashizume, M.; Tanaka, M.

In: Cancer Gene Therapy, Vol. 17, No. 8, 01.08.2010, p. 541-549.

Research output: Contribution to journalArticle

Onimaru, M. ; Ohuchida, K. ; Egami, T. ; Mizumoto, K. ; Nagai, E. ; Cui, L. ; Toma, H. ; Matsumoto, K. ; Hashizume, M. ; Tanaka, M. / Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells. In: Cancer Gene Therapy. 2010 ; Vol. 17, No. 8. pp. 541-549.
@article{265dcb5eb669432da4a32515652fa1ce,
title = "Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells",
abstract = "Adenovirus-mediated gene therapy shows remarkable promise as a new strategy for advanced pancreatic cancer, but satisfactory clinical results have not yet been obtained. To improve this gene therapy, we investigated the effects of gemcitabine (GEM) on transgene expression by adenoviral vectors and their biological effects. We used Ad-lacZ and adenoviral vector-expressing NK4 (Ad-NK4) as representative adenoviral vectors. These vectors express Β-galactosidase (Β-gal) and NK4 (which inhibits the invasion of cancer cells), respectively, under the control of the CMV promoter. Cells were infected with the individual adenoviruses and then treated with GEM. GEM increased Β-gal mRNA expression and Β-gal activity, and increased NK4 expression in both culture media and within infected cells, in dose-dependent manners. The increased expression of NK4 delivered by Ad-NK4 had biological effects by inhibiting the invasion of cancer cells. GEM also enhanced NK4 expression in SUIT-2 cells transfected with an NK4-expressing plasmid, suggesting that GEM enhanced CMV promoter activity. In in vivo experiments, NK4 expression within subcutaneously implanted tumors was increased in GEM-treated mice compared with control mice. These results suggest that adenovirus-mediated gene therapy with GEM may be a promising approach for treating pancreatic cancer, and that this combination therapy may decrease the risks of side effects.",
author = "M. Onimaru and K. Ohuchida and T. Egami and K. Mizumoto and E. Nagai and L. Cui and H. Toma and K. Matsumoto and M. Hashizume and M. Tanaka",
year = "2010",
month = "8",
day = "1",
doi = "10.1038/cgt.2010.9",
language = "English",
volume = "17",
pages = "541--549",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells

AU - Onimaru, M.

AU - Ohuchida, K.

AU - Egami, T.

AU - Mizumoto, K.

AU - Nagai, E.

AU - Cui, L.

AU - Toma, H.

AU - Matsumoto, K.

AU - Hashizume, M.

AU - Tanaka, M.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Adenovirus-mediated gene therapy shows remarkable promise as a new strategy for advanced pancreatic cancer, but satisfactory clinical results have not yet been obtained. To improve this gene therapy, we investigated the effects of gemcitabine (GEM) on transgene expression by adenoviral vectors and their biological effects. We used Ad-lacZ and adenoviral vector-expressing NK4 (Ad-NK4) as representative adenoviral vectors. These vectors express Β-galactosidase (Β-gal) and NK4 (which inhibits the invasion of cancer cells), respectively, under the control of the CMV promoter. Cells were infected with the individual adenoviruses and then treated with GEM. GEM increased Β-gal mRNA expression and Β-gal activity, and increased NK4 expression in both culture media and within infected cells, in dose-dependent manners. The increased expression of NK4 delivered by Ad-NK4 had biological effects by inhibiting the invasion of cancer cells. GEM also enhanced NK4 expression in SUIT-2 cells transfected with an NK4-expressing plasmid, suggesting that GEM enhanced CMV promoter activity. In in vivo experiments, NK4 expression within subcutaneously implanted tumors was increased in GEM-treated mice compared with control mice. These results suggest that adenovirus-mediated gene therapy with GEM may be a promising approach for treating pancreatic cancer, and that this combination therapy may decrease the risks of side effects.

AB - Adenovirus-mediated gene therapy shows remarkable promise as a new strategy for advanced pancreatic cancer, but satisfactory clinical results have not yet been obtained. To improve this gene therapy, we investigated the effects of gemcitabine (GEM) on transgene expression by adenoviral vectors and their biological effects. We used Ad-lacZ and adenoviral vector-expressing NK4 (Ad-NK4) as representative adenoviral vectors. These vectors express Β-galactosidase (Β-gal) and NK4 (which inhibits the invasion of cancer cells), respectively, under the control of the CMV promoter. Cells were infected with the individual adenoviruses and then treated with GEM. GEM increased Β-gal mRNA expression and Β-gal activity, and increased NK4 expression in both culture media and within infected cells, in dose-dependent manners. The increased expression of NK4 delivered by Ad-NK4 had biological effects by inhibiting the invasion of cancer cells. GEM also enhanced NK4 expression in SUIT-2 cells transfected with an NK4-expressing plasmid, suggesting that GEM enhanced CMV promoter activity. In in vivo experiments, NK4 expression within subcutaneously implanted tumors was increased in GEM-treated mice compared with control mice. These results suggest that adenovirus-mediated gene therapy with GEM may be a promising approach for treating pancreatic cancer, and that this combination therapy may decrease the risks of side effects.

UR - http://www.scopus.com/inward/record.url?scp=77954814659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954814659&partnerID=8YFLogxK

U2 - 10.1038/cgt.2010.9

DO - 10.1038/cgt.2010.9

M3 - Article

C2 - 20395979

AN - SCOPUS:77954814659

VL - 17

SP - 541

EP - 549

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -